Literature DB >> 14635979

Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension.

D Mukerjee1, L B Yap, A M Holmes, D Nair, P Ayrton, C M Black, J G Coghlan.   

Abstract

OBJECTIVES: A single centre pilot study to investigate the role of the plasma N-terminal pro-brain natriuretic peptide (N-T proBNP) assay to risk stratify patients with suspected pulmonary arterial hypertension (PAH) from a background SSc population.
METHODS: Out of 49 SSc patients, 23 had and 26 did not have PAH. Right ventricular haemodynamic variables, six-minute walk test and plasma N-T proBNP levels were recorded from patients catheterised for suspected PAH (23 with PAH and 11/26 without PAH).
RESULTS: Mean value of N-T proBNP for SSc patients with PAH was 3365 (standard error 1095) pg/ml compared to 347 (174) pg/ml for patients without PAH. There was a statistically significant correlation (P < 0.05) between N-T proBNP values and (i) mean pulmonary artery pressure (r = 0.53), (ii) right ventricular end diastolic pressure (r = 0.59) and (iii) pulmonary vascular resistance (r = 0.49). Receiver operator characteristic curve analysis showed that a cut-off value of 395.34 pg/ml had a sensitivity of 0.69 and specificity of 1.0.
CONCLUSIONS: N-T proBNP estimation in systemic sclerosis-related pulmonary hypertension is a potentially useful diagnostic tool with a high specificity and negative predictive value. This test has the potential to have an important role in risk stratification and monitoring of therapy in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635979     DOI: 10.1016/s0954-6111(03)00254-3

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

Review 1.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

2.  The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.

Authors:  Hyo Jin Choi; Young Kee Shin; Hyun Joo Lee; Joo Young Kee; Dong Woo Shin; Eun Young Lee; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2007-09-25       Impact factor: 2.980

3.  N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Haralambos Karvounis; Georgios Koliakos; Tilemahos Sfetsios; Hara Dimitroula; Loukas Settas
Journal:  Clin Rheumatol       Date:  2008-01-18       Impact factor: 2.980

4.  Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Klio Papadopoulou; Tilemahos Sfetsios; Haralambos Karvounis; Hariklia Dimitroula; Despina Parcharidou; Georgios Koliakos; Alexandros Garyfallos; Ioannis Styliadis; Loukas Settas
Journal:  Clin Rheumatol       Date:  2010-06-05       Impact factor: 2.980

Review 5.  Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review.

Authors:  Heather Gladue; Nezam Altorok; Whitney Townsend; Vallerie McLaughlin; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2013-09-05       Impact factor: 5.532

6.  Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Hariklia Dimitroula; Tilemahos Sfetsios; Despina Parcharidou; Haralambos Karvounis; Loukas Settas
Journal:  Rheumatol Int       Date:  2010-07-25       Impact factor: 2.631

Review 7.  Early detection of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Marc Humbert; David S Celermajer
Journal:  Nat Rev Cardiol       Date:  2014-11-25       Impact factor: 32.419

8.  N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.

Authors:  Sara Simeoni; Giuseppe Lippi; Antonio Puccetti; Martina Montagnana; Elisa Tinazzi; Daniele Prati; Roberto Corrocher; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2007-12-19       Impact factor: 2.631

9.  Therapy of pulmonary arterial hypertension in systemic sclerosis: an update.

Authors:  Christopher P Denton; Svetlana I Nihtyanova
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.